Alcon Inc. · ALC · FY2026 Q3 · Calendar Q4 2026
Alcon holds FY outlook as new launches meet IOL competition
The supplied analysis supports a measured growth case: Alcon reported continued sales growth and maintained its full-year outlook, with product launches, premiumization and contact-lens share gains as potential drivers. That case is balanced by U.S. implantable IOL competition and execution, adoption and margin uncertainties around launches and its acquisition.
Research this report with FN2. Free to start; review your question before sending.
Earnings scorecard
Reported versus consensusMarket reaction
event-close to next-session closeAsk FN2 about ALC FY2026 Q3
Choose a question to continue your researchFree to start. Your question opens in chat for you to review and send. FN2 can look up the transcript, financials and prior quarters.
Transcript intelligence
What changed
Compared with the prior-quarter analysis, the Q3 account centers on sales growth meeting the guidance midpoint and a maintained full-year outlook. The supplied analysis also identifies the Neurotech acquisition and ENCELTO launch, FDA approvals for Vivity Pro and BRYTLY, and ongoing U.S. premium IOL competition as salient developments.
Guidance delta
Management maintained the full-year outlook, described in the supplied analysis as approximately 6% sales growth and double-digit core EPS growth. No change to guidance was reported.
Key takeaways
- UNITY platform momentum and contact-lens share gains were highlighted as contributors to the quarter.
- Management maintained its full-year outlook.
- The portfolio of launches includes Vivity Pro, TruPlus, BRYTLY and ENCELTO; adoption and commercial execution remain important.
- Competitive pressure in U.S. implantable IOLs remains a counterweight to the growth case.
Management priorities
- Commercialize new products and expand premiumization across contact lenses and IOLs.
- Advance the dry-eye franchise and newer retinal and ocular-health opportunities.
- Continue the efficiency program and integrate and commercialize the Neurotech acquisition.
Follow ALC with an agent that reads every filing, transcript, and price print. Free to start.
Try FN2 freeEarnings History
Analyst 52W Price Targets
Latest persisted target per named analyst; persisted current price from FN2's market snapshot as of Nov 22, 2026. Not an FN2 forecast.
Firm-level rating actions
FMP grade actions identify the grading firm, not a named analyst.
| Firm | Rating | Prior rating | Action | Date |
|---|---|---|---|---|
| Stifel | Hold | Hold | Maintain | Nov 12, 2026 |
| Barclays | Equal Weight | Equal Weight | Maintain | Nov 12, 2026 |
| Baird | Outperform | Outperform | Maintain | Nov 12, 2026 |
| Needham | Buy | Buy | Maintain | Nov 11, 2026 |
| BTIG | Buy | Buy | Maintain | Nov 11, 2026 |
| Keybanc | Overweight | Overweight | Maintain | Oct 27, 2026 |
| Jefferies | Buy | Buy | Maintain | Sep 22, 2026 |
| Mizuho | Outperform | Outperform | Maintain | Aug 12, 2026 |
| JP Morgan | Neutral | Neutral | Maintain | Aug 12, 2026 |
| Wells Fargo | Overweight | Overweight | Maintain | May 7, 2026 |
| B of A Securities | Underperform | Buy | Downgrade | Dec 11, 2025 |
| Morgan Stanley | Equal Weight | Equal Weight | Maintain | Aug 21, 2025 |
| Redburn Atlantic | Neutral | Sell | Upgrade | Oct 10, 2024 |
| RBC Capital | Outperform | Sector Perform | Upgrade | Sep 10, 2024 |
| Oppenheimer | Outperform | Outperform | Maintain | Aug 22, 2024 |
| Argus Research | Buy | Buy | Maintain | Mar 4, 2024 |
| Bernstein | Outperform | Outperform | Maintain | Feb 29, 2024 |
| Societe Generale | Sell | Hold | Downgrade | Nov 17, 2022 |
| Citigroup | Neutral | Neutral | Maintain | Nov 17, 2022 |
| Stephens & Co. | Overweight | Equal Weight | Upgrade | May 12, 2022 |
| Credit Suisse | Outperform | Outperform | Maintain | Feb 17, 2022 |
| SVB Leerink | Market Perform | Market Perform | Maintain | Aug 19, 2021 |
| UBS | Buy | Neutral | Upgrade | Mar 13, 2020 |
| Bank of America | Neutral | Neutral | Maintain | Aug 21, 2019 |
| BMO Capital | Perform | Market Perform | Maintain | Apr 18, 2019 |
| Berenberg | Hold | Hold | Maintain | Apr 10, 2019 |
Named analyst price targets
Upside is calculated against the persisted current price $74.31. FMP does not supply a rating on these named-analyst rows.
| Firm | Analyst | 52W target | Price when posted | Upside | Date |
|---|---|---|---|---|---|
| Bernstein | Susannah Ludwig | $88.9 | $72.8 | +19.6% | Nov 12, 2026 |
| Needham | David Saxon | $98 | $71.45 | +31.9% | Nov 2, 2026 |
| KeyBanc | Analyst unavailable | $84 | $69.99 | +13.0% | Oct 27, 2026 |
| BTIG | Analyst unavailable | $74 | $64.14 | -0.4% | Oct 12, 2026 |
| Barclays | Christopher Pasquale | $70 | $63.19 | -5.8% | Oct 6, 2026 |
| Jefferies | Michael Sarcone | $85 | $65.34 | +14.4% | Sep 22, 2026 |
| BNP Paribas | Analyst unavailable | $79 | $73.58 | +6.3% | Aug 13, 2026 |
| UBS | Analyst unavailable | $35 | $72.87 | -52.9% | Aug 12, 2026 |
| Mizuho Securities | Steve Lichtman | $85 | $75.35 | +14.4% | Aug 12, 2026 |
| BTIG | Ryan Zimmerman | $82 | $75.22 | +10.3% | Aug 11, 2026 |
| Mizuho Securities | Analyst unavailable | $80 | $66.86 | +7.7% | Jul 15, 2026 |
| Argus Research | Analyst unavailable | $85 | $68.7 | +14.4% | Jul 2, 2026 |
| Barclays | Analyst unavailable | $78 | $63.88 | +5.0% | May 8, 2026 |
| Stifel Nicolaus | Analyst unavailable | $70 | $65.5 | -5.8% | May 6, 2026 |
| Stifel Nicolaus | Analyst unavailable | $82 | $81.85 | +10.3% | Mar 9, 2026 |
| Wells Fargo | Larry Biegelsen | $97 | $86.27 | +30.5% | Feb 26, 2026 |
| Stifel Nicolaus | Analyst unavailable | $80 | $80.62 | +7.7% | Jan 9, 2026 |
| Bernstein | Susannah Ludwig | $101.09 | $77.67 | +36.0% | Nov 14, 2025 |
| KeyBanc | Analyst unavailable | $91 | $75.46 | +22.5% | Oct 21, 2025 |
| UBS | Analyst unavailable | $91 | $72.05 | +22.5% | Oct 13, 2025 |
| Barclays | Matt Miksic | $86 | $72.05 | +15.7% | Oct 13, 2025 |
| Stifel Nicolaus | Thomas Stephan | $85 | $73.92 | +14.4% | Sep 29, 2025 |
| BTIG | Ryan Zimmerman | $100 | $87.49 | +34.6% | Jul 14, 2025 |
| KeyBanc | Brett Fishbin | $107 | $97.59 | +44.0% | Oct 15, 2024 |
| Oppenheimer | Steven Lichtman | $110 | $95.56 | +48.0% | Aug 22, 2024 |
| Morgan Stanley | Patrick Wood | $85 | $89.96 | +14.4% | Jul 15, 2024 |
| Mizuho Securities | Anthony Petrone | $105 | $89.97 | +41.3% | May 16, 2024 |
| Oppenheimer | Steve Lichtman | $103 | $89.28 | +38.6% | May 15, 2024 |
| Robert W. Baird | Jeff Johnson | $104 | $89.28 | +40.0% | May 15, 2024 |
| Wells Fargo | Larry Biegelsen | $94 | $89.28 | +26.5% | May 15, 2024 |
| Stifel Nicolaus | Tom Stephan | $100 | $89.28 | +34.6% | May 14, 2024 |
| Jefferies | Anthony Petrone | $105 | $89.28 | +41.3% | May 14, 2024 |
| KeyBanc | Brett Fishbin | $96 | $89.28 | +29.2% | May 14, 2024 |
| Needham | David Saxon | $101 | $88.99 | +35.9% | May 14, 2024 |
| BTIG | Ryan Zimmerman | $92 | $88.96 | +23.8% | May 14, 2024 |
| Goldman Sachs | Richard Felton | $100 | $82.68 | +34.6% | Apr 10, 2024 |
| Bernstein | Susannah Ludwig | $76 | $76.88 | +2.3% | Jan 23, 2024 |
| Robert W. Baird | Jeff Johnson | $90 | $74.31 | +21.1% | May 10, 2023 |
| BTIG | Analyst unavailable | $78 | $67.91 | +5.0% | Dec 21, 2022 |
| Citigroup | Analyst unavailable | $69 | $66.33 | -7.1% | Nov 17, 2022 |
| Argus Research | John Staszak | $78 | $66.4 | +5.0% | Jun 23, 2022 |
| Stephens | Chris Cooley | $86 | $77.17 | +15.7% | Jan 23, 2022 |
| Goldman Sachs | Veronika Dubajova | $94.08 | $78.4 | +26.6% | Nov 30, 2021 |
| Berenberg Bank | Scott Bardo | $96.22 | $83.53 | +29.5% | Nov 17, 2021 |
| Citigroup | Joanne Wuensch | $87 | $81.46 | +17.1% | Nov 11, 2021 |
| Deutsche Bank | Falko Friedrichs | $90.87 | $82.64 | +22.3% | Nov 10, 2021 |
| Argus Research | John Staszak | $88 | $78.5 | +18.4% | Oct 8, 2021 |
| Wells Fargo | Larry Biegelsen | $93 | $83.95 | +25.2% | Sep 13, 2021 |
| UBS | Michael Leuchten | $90.87 | $80.69 | +22.3% | Aug 23, 2021 |
| Societe Generale | Delphine Le Louet | $82.85 | $80.71 | +11.5% | Aug 20, 2021 |
| Leerink Partners | Richard Newitter | $82 | $71.36 | +10.3% | Aug 17, 2021 |
Track every rating change on ALC the moment it posts. Free to start.
Start freeCompany context
Snapshot as of publicationAlcon Inc. researches, develops, manufactures, distributes, and sells eye care products worldwide. The company operates through two segments, Surgical and Vision Care. It offers equipment, instrumentation and diagnostics, intraocular lenses (IOLs), and other implantables; and consumables, including viscoelastics, surgical solutions, incisional instruments, surgical custom packs, and other products for surgical procedures. The company’s cataract products include Unity CS, LenSx laser system, Verion reference unit and Verion digital marker, ARGOS biometer, SMARTCATARACT health platform, NGENUITY 3D visualization system, LuxOR surgical ophthalmic microscope, and ORA system for intra-operative measurements; ADI cloud-based platform; and implantable products, including monofocal, Toric, and Presbyopia-Correcting IOLs, as well as delivery systems, such as…
Historical context
All ALC earningsHealthcare peers this season
Latest reports in the same sector| Company | Quarter | EPS surprise | Market move | Headline |
|---|---|---|---|---|
| ASND Ascendis Pharma A/S | FY2026 Q3 · Calendar Q4 2026 | +38.7% | +3.0% | Ascendis Q3 growth broadens the story, while execution risks remain |
Latest beats and misses
Who reports nextBeat on EPS
- INTUFY2027 Q1 · November 19, 2026+18.3% EPS-6.2% move
- ROSTFY2026 Q3 · November 19, 2026+2.1% EPS-2.8% move
- ESTCFY2027 Q2 · November 19, 2026+16.2% EPS+2.0% move
- KEYSFY2026 Q4 · November 19, 2026+7.1% EPS-1.5% move
- WSMFY2026 Q3 · November 19, 20260.0% EPS-15.2% move
- WMGFY2026 Q4 · November 19, 2026+50.9% EPS-0.6% move
Missed on EPS
- NTESFY2026 Q3 · November 19, 2026-12.8% EPS-11.4% move
- FUTUFY2026 Q3 · November 19, 2026-7.8% EPS+4.8% move
- BABAFY2027 Q2 · November 19, 2026-29.2% EPS-1.3% move
- SQMFY2026 Q3 · November 17, 2026-3.0% EPS-5.5% move
- VIKFY2026 Q3 · November 17, 2026-12.6% EPS+4.4% move
- XPFY2026 Q3 · November 16, 2026-3.0% EPS-2.5% move
Get the ALC recap when the next report posts
One email per quarter with the scorecard, the market reaction and what changed on the call. No account needed.
Sources
- Earnings call transcript and parsed analysis · 2026-11-11T20:10:51.921415+00:00
- FN2 earnings calendar · 2026-11-11T01:23:13.633975+00:00
- Polygon adjusted daily market bars · 2026-11-11T20:20:45.409194+00:00
- Financial Modeling Prep analyst price-target consensus and quote snapshot · 2026-11-11T20:20:45.405479+00:00
Methodology
Reported and consensus figures come from FN2's earnings event records. Market reaction and volume are calculated from daily adjusted bars around the event; abnormal move subtracts the SPY move over the same window.
Analyst target low, average, and high values are derived at request time from each named analyst's latest persisted FMP target. The current-price marker comes from FN2's persisted market snapshot. They are sell-side estimates, not an FN2 valuation or recommendation.
Transcript intelligence is a structured synthesis of the current and prior earnings-call analyses. Missing values stay missing and are never estimated.
By FN2 Research · Updated · As of 2026-11-11. For educational purposes only; not investment advice.